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BACKGROUND: Chemotherapy-induced neutropenia has been associated with prolonged survival selectively in patients on a conven-
tional schedule (combined 5-fluorouracil, leucovorin, and oxaliplatin [FOLFOX2]) but not on a chronomodulated schedule of the same
drugs administered at specific circadian times (chronoFLO4). The authors hypothesized that the early occurrence of chemotherapy-
induced symptoms correlated with circadian disruption would selectively hinder the efficacy of chronotherapy. METHODS: Fatigue and
weight loss (FWL) were considered to be associated with circadian disruption based on previous data. Patients with metastatic colo-
rectal cancer (n5543) from an international phase 3 trial comparing FOLFOX2 with chronoFLO4 were categorized into 4 subgroups
according to the occurrence of FWL or other clinically relevant toxicities during the initial 2 courses of chemotherapy. Multivariate
Cox models were used to assess the role of toxicity on the time to progression (TTP) and overall survival (OS). RESULTS: The propor-
tions of patients in the 4 subgroups were comparable in both treatment arms (P5.77). No toxicity was associated with TTP or OS on
FOLFOX2. The median OS on FOLFOX2 ranged from 16.4 (95% confidence limits [CL], 7.2-25.6 months) to 19.8 months (95% CL, 17.7-
22.0 months) according to toxicity subgroup (P5.45). Conversely, FWL, but no other toxicity, independently predicted for signifi-
cantly shorter TTP (P<.0001) and OS (P5.001) on chronoFLO4. The median OS on chronoFLO4 was 13.8 months (95% CL, 10.4-17.2
months) or 21.1 months (95% CL, 19.0-23.1 months) according to presence or absence of chemotherapy-induced FWL, respectively.
CONCLUSIONS: Early onset chemotherapy-induced FWL was an independent predictor of poor TTP and OS only on chronotherapy.
Dynamic monitoring to detect early chemotherapy-induced circadian disruption could allow the optimization of rapid chronotherapy
and concomitant improvements in safety and efficacy. Cancer 2013;119:2564-73. VC 2013 American Cancer Society.
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INTRODUCTION
The correlation between chemotherapy-induced toxicity and efficacy has been investigated extensively in patients with
various cancers at different disease stages. Consequently, the current thinking is that adverse events are valid surrogate
markers of adequate chemotherapy exposure.1 Thus, clinical studies have repeatedly demonstrated that a lack of drug-
specific toxicities is associated with poor survival outcomes.2-9 For instance, neutropenia was reported as an independent
predictor of prolonged survival in patients receiving chemotherapy for metastatic colorectal cancer.5,10 We recently
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confirmed this finding in patients who were receiving a
conventional schedule of 5-fluorouracil, leucovorin, and
oxaliplatin (FOLFOX2) in an international randomized
trial.10 However, no positive relation between neutrope-
nia and survival was observed in patients who were receiv-
ing a circadian-based schedule involving the
chronomodulated delivery of the same drugs at selected
times of day or night (chronoFLO4).10 Moreover, the
delivery of chronoFLO4 significantly prolonged overall
survival (OS) in men compared with FOLFOX2, but it
significantly reduced survival in women.11 These findings
were confirmed in a meta-analysis of 3 international
randomized trials.12 Experimental data indeed support
paying careful and specific attention to optimal circadian
dosing of anticancer drugs, and maximal antitumor effi-
cacy usually results from chemotherapy administered near
the circadian time corresponding to best tolerability.13
Circadian rhythms are generated within each cell by mo-
lecular clocks, which consist of interwoven transcription/
translation feedback loops.13,14 The molecular clocks, in
turn, are coordinated by an array of physiologic rhythms
generated by the suprachiasmatic nuclei, a circadian pace-
maker in the hypothalamus.13-15 The circadian timing
system encompasses these molecular, cellular, and physio-
logic components and generates 24-hour rhythms in anti-
cancer drug metabolism and cellular proliferation.13,15,16
The circadian timing system in cancer patients has been
assessed with continuous rest-activity monitoring using a
wrist actigraph, which detected circadian disruption in
approximately 1 in 3 cancer patients.17,18 In a previous
work, baseline circadian disruption was associated
robustly with fatigue and appetite loss in 251 patients
with metastatic colorectal cancer.17-19 Fatigue and appe-
tite loss also were observed in individuals who were suffer-
ing from jet lag or who were engaged in shift work—2
conditions that disrupt the circadian timing system.20,21
Moreover, fatigue and body weight loss, objective yet
unspecific measures of appetite loss, occurred more fre-
quently in cancer patients who had circadian alterations
on chemotherapy.22 Body weight loss also was associated
with decreased physical activity in patients undergoing
actigraphy monitoring.23 For the current investigation,
we hypothesized that early onset fatigue and/or weight
loss reflect chemotherapy-induced circadian disruption, a
condition that interferes selectively with the efficacy of
chronomodulated chemotherapy. To probe this hypothe-
sis, we performed a post hoc analysis of data prospectively
collected for an international, randomized, phase 3 trial
(European Organization for Research and Treatment of
Cancer [EORTC] 05963) that was conducted in 564
chemotherapy-naive patients with metastatic colorectal
cancer who were randomized to receive first-line chemo-
therapy with either chronoFLO4 or FOLFOX2.11
MATERIALS AND METHODS
Study Objectives
For the current study, we examined the primary hypothe-
sis that early onset fatigue and body weight loss, occurring
during the initial 4 weeks of treatment, selectively indicate
a poor prognosis for the survival of patients who are
receiving a fixed chronotherapy schedule for metastatic
colorectal cancer. This symptom cluster was selected as
being related to the occurrence of circadian disruption in
cancer patients who are receiving chemotherapy.10 Sec-
ondary objectives included the prognostic relevance of
other main, severe toxicities that have no known associa-
tion with circadian disruption.10,17-19
Study Population and Chemotherapy Schedules
Patients with chemotherapy-naive, metastatic colorectal
cancer were enrolled in the EORTC 05963 trial between
October 1998 and February 2002.11 They provided writ-
ten informed consent and were randomized to receive
first-line chemotherapy with combined fluorouracil, leu-
covorin, and oxaliplatin either as a chronomodulated
infusion (chronoFLO4) or with a conventional, non
time-stipulated schedule (FOLFOX2). Details of these
schedules have been described elsewhere.11
Study Population and Toxicity Evaluation
The landmark population in this study involved patients
who received at least 2 courses of chemotherapy according
to EORTC 05963. This time span covered the initial 4
weeks on chemotherapy. Clinical and hematologic toxic-
ities were graded after each treatment course according to
the National Cancer Institute Common Toxicity Criteria,
version 2.0. Fatigue and appetite loss were rated by the
physician. Whereas chemotherapy-induced fatigue was
reported after each course, appetite loss was not systemati-
cally assessed. However, body weight was measured sys-
tematically before each chemotherapy course and was
chosen as a surrogate quantitative indicator of decreased
appetite. We considered toxicity clinically meaningful if
the patient experienced either grade 2 fatigue or weight
loss 5% of baseline body weight over the initial 2
courses of chemotherapy. The clinical relevance of the
cutoff values selected a priori for our study has been
described elsewhere.8,22,24
The following toxicities were not considered to be
associated with circadian disruption: diarrhea, stomatitis,
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mucositis, hand-foot syndrome, peripheral sensory neu-
ropathy, nausea, vomiting, leukopenia, neutropenia, ane-
mia, and thrombocytopenia. To distinguish the respective
impact of each type of toxicity, patients in each treatment
group were categorized into 4 subgroups according to the
occurrence of no toxicity (subgroup 1), fatigue-weight
loss only (subgroup 2), fatigue-weight loss associated with
other grade 3 toxic events (subgroup 3), or other grade
3 toxicities only (subgroup 4).
Statistical Methods
The primary endpoint of the current study was the associ-
ation between toxicity and OS, defined as the time
between the end (day 14) of the second treatment course
and the date of death irrespective of cause. Patients who
remained alive at the time the database was locked or who
were lost to follow-up were censored on the date of last in-
formation on vital status. At that date, after a median fol-
low-up of 87 months (range, 68-108 months), 488 events
had occurred (89.9%).
The proportions of patients in each toxicity sub-
group were computed for each treatment modality. The
rates were compared with a 2-sided chi-square test. Actual
dose intensities (per square meter per week) received in
the first 2 courses of chemotherapy and throughout the
whole treatment span were compared between the 4
patient categories with the nonparametric Mann-Whitney
U test. The survival functions of the 4 subgroups, as
defined by the occurrence of fatigue-weight loss and/or
other toxicities after the initial 2 treatment courses, were
estimated using the Kaplan-Meier method and were com-
pared using a log-rank test separately in each treatment
arm. The hazard ratio (HR) of an earlier death associated
with the occurrence of toxicity was estimated using Cox
proportional hazards models separately in each treatment
arm. Multivariate prognostic models for OS included
other parameters that were force-entered, whereas toxicity
category was conditionally added. In the first step, param-
eters that predicted the occurrence of any clinically rele-
vant toxicity (fatigue-weight loss and/or other toxicities)
were identified with a thorough screening of clinical fea-
tures using a binary logistic univariate regression model.
The characteristics included sex, age, baseline body mass
index, World Health Organization performance status at
inclusion, the number of metastatic sites, the percentage
of liver involvement by tumor, dose intensities of 5-fluo-
rouracil and oxaliplatin over the first 2 cycles, previous ad-
juvant chemotherapy, Duke stage at diagnosis, primary
tumor site, surgical resection of the primary tumor, previ-
ous surgery for metastases, baseline leukocyte count, and
baseline alkaline phosphatase level. Upon verification of
the absence of colinearity (r 0.37), these parameters
were added in a block to the prognostic model. For the
second step, the subgroup category according to toxicity
occurrence was added to the multivariate model. The
same statistical procedure was performed to examine the
independent predictive role of chemotherapy-induced
toxicity on the time to progression (TTP), which was cal-
culated from the end of the second course until docu-
mented disease progression, death, or last contact,
whichever occurred first. A similar multivariate Cox haz-
ard regression model was performed separately using the
occurrence of fatigue-weight loss and the occurrence of
other toxicities as covariates to validate the specificity of
either toxicity on TTP and OS for each treatment modal-
ity. Further sensitivity analyses were performed excluding
patients with missing data. Because 2 independent models
were fitted for FOLFOX2 and chronoFLO4 modalities,
the threshold for statistically significant differences was set
at P .025 according to a Bonferroni correction. The rate
of missing data per item for the parameters considered
(blood counts, clinical toxicities, and body weight) after
the first 2 courses of chemotherapy was of 1.3%. Sensitiv-
ity analyses performed that eliminated patients who had
at least 1 missing item yielded results that were strictly
comparable to those reported in the main landmark group
(data not reported). All analyses were performed using
PASW Statistics 18 software (SPSS Inc., Chicago, Ill).
Study Population
Of 564 enrolled and randomized patients in the EORTC
05963 trial, 543 patients (96.3%) received at least 2
courses of chemotherapy and constituted the study popu-
lation (Fig. 1). The clinical and demographic features of
the 272 patients who received FOLFOX2 and the 271
patients who received chronoFLO4 are presented accord-
ing to the occurrence of fatigue-body weight loss and
other toxicities (data not shown).
RESULTS
Dose Intensities and Toxicities
The actual dose intensities of 5-fluororucacil and oxalipla-
tin over the initial 2 treatment courses varied according to
the toxicity category in the FOLFOX2 schedule
(P5 .008 and P5 .001, respectively), but not in the
chronoFLO4 schedule (P5 .24 and P5 .20, respec-
tively). Fatigue-weight loss was encountered in 73 patients
(26.8%) in the FOLFOX2 group and 69 patients
(25.5%) in the chronoFLO4 group (P5 .72), whereas
other toxicities occurred in 40 patients (14.7%) and 54
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patients (19.9%), respectively (P5 .11) (Fig. 2). The co-
occurrence of fatigue-weight loss and other toxicities was
significantly more frequent in the chronoFLO4 group
(n5 27; 10.0%) than in the FOLFOX2 group (n5 14;
5.1%; P5 .036). The relative proportions of patients in
each of the 4 toxicity categories did not differ according to
treatment modality with statistical significance (P5 .07)
(Fig. 2). Women who received chronoFLO4 were signifi-
cantly more likely to develop toxicity than men who
received chronoFLO4 (P5 .003) (Table 1). Patients with
good baseline performance status displayed a significantly
reduced risk of experiencing toxicity after either treatment
schedule (Table 1). The regimen and dosing of supportive
medications, including steroids, were similar in both
treatment arms.11
Tumor Response and Progression-Free Survival
Objective response rates were similar in the 4 toxicity cate-
gories for patients in the FOLFOX2 group (P5 .80)
(Table 2). Conversely, an objective response was achieved
in 22.2% of patients with fatigue-weight loss and other
toxicities on chronoFLO4 compared with from 40.5% up
to 51.9% of patients in the other toxicity subgroups
(P5 .06) (Table 2).
The 4 toxicity categories displayed similar curves for
TTP for patients who received FOLFOX2 (log-rank test;
P5 .11) (Fig. 3A). Conversely, a significant difference in
TTP was observed according to toxicity category among
the patients who received chronoFLO4 (log-rank test;
P< .0001). The patients with fatigue-weight loss dis-
played the worst outcome, irrespective of the association
of this symptom cluster with other toxicities (Fig. 3B).
This translated into a higher risk of earlier progression on
chronoFLO4 for patients with fatigue-weight loss, either
alone (P< .0001) or combined with other toxicities
(P5 .001). No such relation was observed among patients
who had toxicities other than fatigue-weight loss
(P5 .59). Fatigue-weight loss was confirmed as an inde-
pendent prognostic indicator of the risk of earlier progres-
sion on chronoFLO4 using the multivariate Cox model
(P< .001). No such correlation was validated for the
patients who had toxicities other than fatigue-weight loss
Figure 1. This is a flow chart of the 564 patients who were enrolled and randomized on the European Organization for Research
and Treatment of Cancer 05963 trial. FOLFOX2 indicates combined 5-fluorouracil, leucovorin, and oxaliplatin delivered on a con-
ventional schedule; chronoFLO4 indicates combined, 5-fluorouracil, leucovorin, and oxaliplatin delivered on a circadian-based,
chronomodulated schedule.
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(P5 .54) (Table 3). The multivariate models further con-
firmed the lack of predictive value of any toxicity category
for TTP in the patients who received FOLFOX2
(Table 3). In summary, the occurrence of fatigue-weight
loss was not related significantly to TTP in the FOLFOX2
group (P5 .07) (Fig. 3C), whereas it was strongly associ-
ated with a shorter TTP in the chronoFLO4 group
(P< .0001) (Fig. 3D).
Prognostic Value of Toxicity in Overall Survival
OS curves were similar in the 4 toxicity categories
for patients in the FOLFOX2 group (log-rank test;
P5 .45) (Fig. 4A), with similar median survival dura-
tion ranging from 16.4 to 19.8 months (Table 2).
However, the survival of patients in the chronoFLO4
group differed significantly as a function of toxicity
category (log-rank test; P< .0001), with median val-
ues ranging from 13.7 months (fatigue-weight loss
category) to 21.6 months (no clinical toxicity cate-
gory) (Table 2, Fig. 4B). Patients with fatigue-weight
loss in the chronoFLO4 group displayed an increased
risk of earlier death (fatigue-weight loss only,
P5 .002; fatigue-weight loss combined with other
toxicities, P< .0001) compared with patients without
TABLE 1. Univariate Binary Logistic Regression for
the Identification of the Parameters Potentially
Predictive for the Occurrence of Any Toxicity
(Fatigue-Weight Loss, Other, or Both) Separately
in Each Treatment Arma
Toxicity Occurrence
FOLFOX2 ChronoFLO4
Variable OR (95% CI) P OR (95% CI) P
Sex
Men NS 1.00 .003
Women 2.19 (1.32-3.65)
Baseline WHO PS
0 1.00 .006 1.00 .028
1 1.29 (0.76-2.19) 1.44 (0.84-2.47)
2 4.48 (1.78-11.27) 2.94 (1.32-6.56)
No. of metastatic sites
1 1.00 .05 NS
2 0.94 (0.52-1.68)
3 1.97 (1.05-3.68)
Quantitative dose intensity
l-OHP, mg/m2/wk NS 0.96 (0.92-0.998) .038
5-FU, g/m2/wk 0.11 (0.02-0.55) .007 0.15 (0.04-0.56) .004
Abbreviations: 5-FU, 5-fluororuacil; ChronoFLO4, 5-fluorouracil, leucovorin,
and oxaliplatin delivered on a circadian-based, chronomodulated schedule;
CI, confidence interval; FOLFOX2, 5-fluorouracil, leucovorin, and oxaliplatin
delivered on a conventional schedule; l-OHP, oxaliplatin; NS, nonsignificant;
OR, odds ratio; WHO PS, World Health Organization performance status.
a The complete list of parameters accounted for is provided in the text (see
Materials and Methods). The parameters that were not significant in any
model are not listed here.
Figure 2. Relative proportions of patients without toxicity
(group 1; white), with fatigue-weight loss only (group 2; blue),
with both fatigue-weight loss and other toxicities (group 3;
blue and red stripes), and with other toxicities only (group 4;
red) are illustrated for each treatment arm. FOLFOX2 indi-
cates combined 5-fluorouracil, leucovorin, and oxaliplatin
delivered on a conventional schedule; chronoFLO4, 5-fluo-
rouracil, leucovorin, and oxaliplatin delivered on a circadian-
based, chronomodulated schedule.
TABLE 2. Clinical Outcomes (Objective Response
Rate, Time to Progression, and Overall Survival)
According to Toxicity Category Separately in Each
Treatment Arm
Outcome
Treatment Arm
ORR
(95% Cl), %
Median TTP
(95% CI), mo
Median OS
(95% CI), mo
FOLFOX2
Group 1, n5 175a 48 (40.6-55.40) 9.1 (8.0-10.2) 19.8 (17.7-22.0)
Group 2, n5 42 40.7 (25.8-55.6) 6.1 (3.4-8.9) 17.1 (12.2-22.0)
Group 3, n5 27 42.9 (24.2-61.6) 5.6 (3.0-8.2) 16.4 (7.2-25.6)
Group 4, n5 27 42.2 (23.6-60.8) 8.5 (6.1-10.9) 19.6 (15.7-23.4)
All, n5 271 46 (40.1-51.9) 8.7 (7.9-9.4) 18.6 (17.0-20.1)
ChronoFLO4
Group 1, n5 173 48.6 (41.2-56.1) 9.4 (8.5-10.4) 21.6 (19.2-24.0)
Group 2, n5 59 40.5 (28-53) 6.0 (3.9-8.2) 13.7 (8.8-18.6)
Group 3, n5 14 22.2 (0.5-44) 5.6 (3.1-8.2) 13.9 (8.6-19.2)
Group 4, n5 26 51.9 (32.7-71.1) 10.2 (5.8-14.6) 19.1 (12.6-25.7)
All, n5 272 45 (39.1-50.9) 8.4 (7.4-9.3) 19.7 (18.4-21.0)
Abbreviations: ChronoFLO4, 5-fluorouracil, leucovorin, and oxaliplatin deliv-
ered on a circadian-based, chronomodulated schedule; CI, confidence
interval; FOLFOX2, 5-fluorouracil, leucovorin, and oxaliplatin delivered on a
conventional schedule; ORR, objective response rate; OS, overall survival;
TTP, time to progression.
aGroup 1: no toxicity; 2: fatigue-weight loss only; 3: both fatigue-weight
loss and other toxicities; 4: other toxicities only.
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any toxicity in this group. No difference in survival
was observed between among patients who received
chronoFLO4 according to toxicities other than fa-
tigue-weight loss (P5 .37).
The increased risk of earlier death associated with fa-
tigue-weight loss on chronoFLO4, either alone
(P5 .009) or combined with other toxicities (P5 .006),
remained significant, independent of the other known
prognostic factors and parameters associated with these
toxicities in a multivariate Cox model (Table 3). The
models confirmed the lack of prognostic value for toxic-
ities other than fatigue-weight loss in the chronoFLO4
group and for any toxicity category in the FOLFOX2
group (Table 3).
Figure 3. These Kaplan-Meier curves depict the time to progression in each treatment arm: (A,C) combined 5-fluorouracil, leucov-
orin, and oxaliplatin delivered on a conventional schedule (FOLFOX2) and (B,D) 5-fluorouracil, leucovorin, and oxaliplatin deliv-
ered on a circadian-based, chronomodulated schedule (chronoFLO4). (A,B) Curves illustrate the time to progression for the 4
patient groups categorized according to the occurrence of no toxicity (group 1; solid black lines), fatigue-weight loss only (group
2; solid blue lines), both fatigue-weight loss and other toxicities (group 3; dashed blue and red lines), and other toxicities only
(group 4; solid red lines). (C,D) Curves illustrate the time to progression for the 4 patient groups categorized according to the
occurrence of fatigue-weight loss (groups 2 and 3; solid blue lines) and the absence of fatigue-weight loss (groups 1 and 4;
dashed black lines). P values were calculated with the log-rank test.
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In aggregate, OS was not influenced by the occur-
rence of fatigue-weight loss (P5 .12) (Fig. 4C) or other
toxicities (P5 .89; results not shown) for patients in the
FOLFOX2 group. Conversely, a higher risk of earlier
death resulted from the occurrence of fatigue-weight loss
(Fig. 4D) (P< .0001) and other toxicities (P5 .022;
results not shown) in the chronoFLO4 group. The multi-
variate Cox model ruled out other clinical toxicities as pre-
dictors of OS (P5 .08; results not shown). However, the
fatigue-weight loss cluster remained a statistically signifi-
cant predictor of poor survival in this analysis (P5 .001).
DISCUSSION
This study revealed that the advent of fatigue or weight loss
during the initial 4 weeks on chemotherapy predicted poor
progression-free survival and OS on a fixed chronotherapy
schedule in patients with metastatic colorectal cancer. No
such relation was observed between these symptoms and ef-
ficacy outcomes in patients who received conventional
chemotherapy. The current study also demonstrated no
predictive value of other severe clinical toxicities for any effi-
cacy outcome regardless of the delivery schedule. Thus, the
current report constitutes the first clinical proof of a nega-
tive relation between toxicity and both TTP and survival in
oncology. Prior studies consistently reported a positive asso-
ciation between specific toxicities and clinical outcomes in
patients who received various chemotherapies for many
kinds of malignancies.2-9 The specificity of the current find-
ing for chronotherapy delivery supports a shared circadian
biologic mechanism correlating poor anticancer activity
with poor tolerability.13 Fatigue-weight loss was high-
lighted here as a critical symptom cluster that may impair
the efficacy of chronotherapy. Fatigue, anorexia, and body
weight loss are frequent chemotherapy-induced complaints
that often cluster and may share common mecha-
nisms.19,22,25-28 Prior studies supported the hypothesis that
the fatigue-weight loss symptom cluster would result from
circadian disruption.19,22 Therefore, we chose the occur-
rence of this cluster of systemic toxicity as an indirect surro-
gate for chemotherapy-induced circadian disruption.
In the current work, no difference in overall toxicity
rates during the initial 2 courses of treatment was observed
as a function of treatment schedule (Fig. 2). However,
early toxicities on chronoFLO4 were almost twice as fre-
quent in women compared with men. Hence, the higher
toxicity incidence in women may have been particularly
detrimental for the efficacy of chronomodulated chemo-
therapy, which is based biologically on a coordinated,
TABLE 3. Variables Included in the Multivariate Cox Proportional Hazard Models for Time to Progression
and Overall Survival Separately in Each Treatment Arm
Time to Progression Overall Survival
FOLFOX2 ChronoFLO4 FOLFOX2 ChronoFLO4
Variable HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Sex
Men NS 1.00 .012 1.00 .001 1.00 .013
Women 1.42 (1.08-1.87) 0.61 (0.46-0.82) 1.43 (1.08-1.89)
Baseline WHO PS
0 1.00 <.0001 NS 1.00 <.0001 NS
1 1.49 (1.12-1.97) 1.51 (1.13-2.01)
2 2.82 (1.67-4.75) 4.43 (2.53-7.76)
No. of metastatic sites
1 NS NS 1.00 <.0005 NS
2 1.17 (0.85-1.60)
3 1.81 (1.23-2.62)
Baseline ALP, IU/L
300 1.00 .002 NS 1.00 <.0001 NS
>300 1.74 (1.25-2.49) 2.02 (1.44-2.83)
Unknown 1.67 (0.83-3.39) 1.31 (0.64-2.70)
Toxicity group
1) No toxicity NS 1.00 .002 NS 1.00 .006
2) Fatigue-weight loss only 1.80 (1.23-2.67) 1.65 (1.13-2.39)
3) Both fatigue-weight
loss and other toxicities
1.82 (1.14-2.92) 1.92 (1.20-3.05)
4) Other toxicities only 0.87 (0.55-1.37) 1.30 (0.82-2.07)
Abbreviations: ALP, alkaline phosphatase, ChronoFLO4, 5-fluorouracil, leucovorin, and oxaliplatin delivered on a circadian-based, chronomodulated schedule;
CI, confidence interval; FOLFOX2, 5-fluorouracil, leucovorin, and oxaliplatin delivered on a conventional schedule; HR, hazard ratio; NS, nonsignificant; WHO
PS, World Health Organization performance status.
Original Article
2570 Cancer July 15, 2013
functional biologic clock.13-16,29 Thus, wrongly dosed or
poorly timed circadian chemotherapy could disrupt both
the central pacemaker and the peripheral oscillators,
resulting in symptoms of circadian disruption (fatigue,
anorexia, weight loss) and toxic effects in peripheral tis-
sues, which are equipped with functional molecular
clocks.16,30,31
The current findings indicate that chemotherapy-
induced circadian disruption, as estimated here with the
occurrence of fatigue or weight loss, may be detrimental
for the efficacy of circadian-based chemotherapy. This is
not be the case, however, for conventional chemotherapy,
in which the timing of administration varies both between
and within patients.13
Figure 4. These Kaplan-Meier curves depict overall survival in each treatment arm: (A,C) combined 5-fluorouracil, leucovorin, and
oxaliplatin delivered on a conventional schedule (FOLFOX2) and (B,D) 5-fluorouracil, leucovorin, and oxaliplatin delivered on a
circadian-based, chronomodulated schedule (chronoFLO4). (A,B) Curves illustrate survival for the 4 patient groups categorized
according to the occurrence of no toxicity (group 1; solid black lines), fatigue-weight loss only (group 2; solid blue lines), both fa-
tigue-weight loss and other toxicities (group 3; dashed blue and red lines), and other toxicities only (group 4; solid red lines).
(C,D) Curves illustrate survival for the 4 patient groups categorized according to the occurrence of fatigue-weight loss (groups 2
and 3; solid blue lines) and the absence of fatigue-weight loss (groups 1 and 4; dashed black lines). P values were calculated with
the log-rank test.
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Two main limitations of the current study should be
acknowledged. First, patients were not randomized to de-
velop toxicity. Therefore, it may be argued that other fac-
tors associated with fatigue-weight loss or other
toxicities would be the main determinants of the sur-
vival differences observed, and toxic events would
merely form a surrogate marker of a poor prognosis
related to other determinants. To rule out this possibil-
ity, we systematically proceeded with a thorough
screening of all parameters that possibly might account
for the induction of either toxicity. All factors were for-
cibly added to the Cox survival model, whereas the
toxicity subgroup category was added conditionally to
the model to explore whether it had independent prog-
nostic value above and beyond the other parameters
considered. Indeed, the occurrence of chemotherapy-
induced fatigue-weight loss remained an independent
prognostic factor for both TTP and OS in the chrono-
FLO4 group despite the adjustment for the other pa-
rameters and known prognostic factors. This analysis
confirmed the prognostic relevance of sex for chrono-
therapy12 along with the relevance of PS and alkaline
phosphatase for conventional chemotherapy32,33 (Table
3). Second, the grading of fatigue is subjective, with
uncertain reliability and reproducibility. However, in 2
large meta-analyses that included individual data
reporting subjective parameters, PS or patient self-esti-
mated quality-of-life measures at baseline independ-
ently predicted OS.33,34 Thus, pertinent subjective
parameters added relevant prognostic information to
that derived from objective measures.
Furthermore, circadian function can be quantified
both noninvasively and objectively in cancer patients
using wrist actimetry monitoring.17,18,35 The early detec-
tion of circadian disruption indeed may readily help its
minimization through the modification of drug doses
and/or timing administration, resulting in personalized
rather than fixed chronotherapy schedules.
In conclusion, the patients who displayed fatigue-
weight loss within the initial 4 weeks of a fixed chrono-
therapy schedule were less likely to benefit from it. This
finding provides a clinically relevant tool for further treat-
ment optimization, which also may benefit from a quanti-
tative dynamic approach based on circadian rhythm
monitoring. A main implication of the current study,
which deserves prospective validation, is that circadian-
based schedules should achieve low toxicity to optimize ef-
ficacy, a finding that also has been supported experimen-
tally.13 This paradigm seems to be specific for
chronotherapy. It contrasts with the current concept of
conventional chemotherapy, in which the maximum tol-
erated dose of an anticancer drug represents the optimal
therapeutic dose.
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